Keith W. Pratz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keith W. Pratz has a total of 331 co-authors. Here are the top co-authors by number of shared publications:
- Courtney Denton Dinardo
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA
21 shared publications - Brian A. Jonas
Division of Malignant Hematology/Cellular Therapy and Transplantation, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA
17 shared publications - Christian Récher
CHU de Toulouse, Toulouse, France
17 shared publications - Vinod Pullarkat
City of Hope National Medical Center Duarte California USA
14 shared publications - Andrew H. Wei
Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
13 shared publications - Andre C. Schuh
Princess Margaret Cancer Centre, Toronto, Canada
12 shared publications
Latest Publications
- 9 January 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (4) , 926-929
Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies
- 9 January 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (4) , 926-929
Long‐Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax‐Based Therapies
- Open Access
- 28 March 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-5
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
- 28 March 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-5
Open AccessVenetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia
- 17 February 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (S2) , 16-22
Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Backbone therapy for acute myeloid leukemia for younger adults has for 50 years been based on a combination of cytarabine and anthracycline. Over the past 10 years the addition of several targeted agents has been found to improve the outcomes of subsets of AML with particular molecular changes. In this review we will examine the data generated to date on the addition of agents targeting CD33, FLT3, IDH, and BCL2 to standard high intensity therapies. We will also review the potential for future studies evaluating the application of highly active lower intensity therapies developed in older adults to patients considered “fit for high intensity induction.” Lastly, we review the data around the role of stem cell transplant in the modern targeted era.
- 17 February 2025
- Published by Wiley in American Journal of Hematology
- Vol. 100 (S2) , 16-22
Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Backbone therapy for acute myeloid leukemia for younger adults has for 50 years been based on a combination of cytarabine and anthracycline. Over the past 10 years the addition of several targeted agents has been found to improve the outcomes of subsets of AML with particular molecular changes. In this review we will examine the data generated to date on the addition of agents targeting CD33, FLT3, IDH, and BCL2 to standard high intensity therapies. We will also review the potential for future studies evaluating the application of highly active lower intensity therapies developed in older adults to patients considered “fit for high intensity induction.” Lastly, we review the data around the role of stem cell transplant in the modern targeted era.
- Open Access
- 22 December 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (4) , 1250-1252
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1
Outcomes of myeloproliferative neoplasms (MPN)‐associated acute leukaemias are dismal with conventional therapy. Approximately 20% of MPN‐associated acute leukaemias have mutations in isocitrate dehydrogenase (IDH). Olutasidenib, and inhibitor of IDH1, demonstrates important clinical benefits in MPN‐associated leukaemia with IDH1 mutation.Commentary on: Botton et al. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukemia arising from a prior myeloproliferative neoplasm. Br J Haematol 2025; 206:1121‐1128.
- 22 December 2024
- Published by Wiley in British Journal of Haematology
- Vol. 206 (4) , 1250-1252
Open AccessAdvancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1
Outcomes of myeloproliferative neoplasms (MPN)‐associated acute leukaemias are dismal with conventional therapy. Approximately 20% of MPN‐associated acute leukaemias have mutations in isocitrate dehydrogenase (IDH). Olutasidenib, and inhibitor of IDH1, demonstrates important clinical benefits in MPN‐associated leukaemia with IDH1 mutation.Commentary on: Botton et al. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukemia arising from a prior myeloproliferative neoplasm. Br J Haematol 2025; 206:1121‐1128.
- Open Access
- 1 November 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 185-188
The impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia
- 1 November 2024
- Published by Wiley in American Journal of Hematology
- Vol. 100 (1) , 185-188
Open AccessThe impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia
- 20 March 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (9) , 984-986
CML and the WHO: Why?
- 20 March 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (9) , 984-986
CML and the WHO: Why?
- Top Cited PapersOpen Access
- 11 February 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (4) , 615-624
Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE‐A study (NCT02993523). Here, long‐term follow‐up is presented to address survival benefit and long‐term outcomes with venetoclax‐azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax‐azacitidine or placebo‐azacitidine. OS was the primary endpoint; complete remission with/without blood count recovery (CR/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE‐A, 431 patients were enrolled to venetoclax‐azacitidine (n = 286) or placebo‐azacitidine (n = 145). At 43.2 months median follow‐up, median OS was 14.7 months (95% confidence interval [CI], 12.1–18.7) with venetoclax‐azacitidine, and 9.6 months (95% CI, 7.4–12.7) with placebo‐azacitidine (hazard ratio, 0.58 [95% CI, 0.47–0.72], p < .001); the estimated 24‐month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with IDH1/2 mutations and those with measurable residual disease responses was reached in this final analysis. CR/CRi rate was similar to interim analysis. Any‐grade hematologic and gastrointestinal adverse events were most common in venetoclax‐azacitidine and placebo‐azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long‐term efficacy and safety confirm venetoclax‐azacitidine is an improvement in standard‐of‐care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.
- 11 February 2024
- Published by Wiley in American Journal of Hematology
- Vol. 99 (4) , 615-624
Top Cited PapersOpen AccessLong‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia
Venetoclax‐azacitidine is approved for treatment of patients with newly diagnosed acute myeloid leukemia (AML) ineligible for intensive chemotherapy based on the interim overall survival (OS) analysis of the VIALE‐A study (NCT02993523). Here, long‐term follow‐up is presented to address survival benefit and long‐term outcomes with venetoclax‐azacitidine. Patients with newly diagnosed AML who were ineligible for intensive chemotherapy were randomized 2:1 to receive venetoclax‐azacitidine or placebo‐azacitidine. OS was the primary endpoint; complete remission with/without blood count recovery (CR/CRi) was a key secondary endpoint. This final analysis was conducted when 100% of the predefined 360 OS events occurred. In VIALE‐A, 431 patients were enrolled to venetoclax‐azacitidine (n = 286) or placebo‐azacitidine (n = 145). At 43.2 months median follow‐up, median OS was 14.7 months (95% confidence interval [CI], 12.1–18.7) with venetoclax‐azacitidine, and 9.6 months (95% CI, 7.4–12.7) with placebo‐azacitidine (hazard ratio, 0.58 [95% CI, 0.47–0.72], p < .001); the estimated 24‐month OS rate was 37.5% and 16.9%, respectively. Median OS for patients with IDH1/2 mutations and those with measurable residual disease responses was reached in this final analysis. CR/CRi rate was similar to interim analysis. Any‐grade hematologic and gastrointestinal adverse events were most common in venetoclax‐azacitidine and placebo‐azacitidine arms, including thrombocytopenia (47% and 42%) and neutropenia (43% and 29%). No new safety signals were identified. Long‐term efficacy and safety confirm venetoclax‐azacitidine is an improvement in standard‐of‐care for patients with AML who are not eligible for intensive chemotherapy because of advanced age or comorbidities.
- 10 September 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (26) , 4236-4246
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
PURPOSE: Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy for adult patients with newly diagnosed, non–favorable-risk AML. METHODS: In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013 ), 103 participants were screened and 80 were allocated to treatment. The study was divided into four parts: dose escalation, dose expansion, investigation of alternate anthracycline and gilteritinib schedule, and continuous gilteritinib during consolidation. RESULTS: After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants with FLT3-mutated AML, the composite complete response (CRc) rate was 89% (83% were conventional complete responses), all achieved after a single induction cycle. The median overall survival time was 46.1 months. Gilteritinib was well-tolerated in this context although the median time to count recovery during induction was approximately 40 days. Longer time-to-count recovery was associated with higher trough levels of gilteritinib, which, in turn, were associated with azole use. The recommended regimen is gilteritinib at a dose of 120 mg once daily from days 4 to 17 or 8 to 21 of a 7 + 3 induction with either idarubicin or daunorubicin and from day 1 continuously with high-dose cytarabine consolidation. Maintenance therapy with gilteritinib was well-tolerated. CONCLUSION: These results demonstrated the safety and tolerability of gilteritinib incorporated into an induction and consolidation chemotherapy regimen, and as single-agent maintenance therapy for patients with newly diagnosed FLT3-mutant AML. The data herein provide an important framework for the design of randomized trials comparing gilteritinib with other FLT3 inhibitors.
- 10 September 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (26) , 4236-4246
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
PURPOSE: Gilteritinib is a type 1 FLT3 inhibitor active as monotherapy for relapsed or refractory FLT3-mutated AML. We investigated the safety, tolerability, and efficacy of gilteritinib incorporated into intensive induction and consolidation chemotherapy, and as maintenance therapy for adult patients with newly diagnosed, non–favorable-risk AML. METHODS: In this phase IB study (2215-CL-0103; ClinicalTrials.gov identifier: NCT02236013 ), 103 participants were screened and 80 were allocated to treatment. The study was divided into four parts: dose escalation, dose expansion, investigation of alternate anthracycline and gilteritinib schedule, and continuous gilteritinib during consolidation. RESULTS: After dose escalation, 120 mg gilteritinib once daily was chosen for further study. There were 58 participants evaluable for response at this dose, 36 of whom harbored FLT3 mutations. For participants with FLT3-mutated AML, the composite complete response (CRc) rate was 89% (83% were conventional complete responses), all achieved after a single induction cycle. The median overall survival time was 46.1 months. Gilteritinib was well-tolerated in this context although the median time to count recovery during induction was approximately 40 days. Longer time-to-count recovery was associated with higher trough levels of gilteritinib, which, in turn, were associated with azole use. The recommended regimen is gilteritinib at a dose of 120 mg once daily from days 4 to 17 or 8 to 21 of a 7 + 3 induction with either idarubicin or daunorubicin and from day 1 continuously with high-dose cytarabine consolidation. Maintenance therapy with gilteritinib was well-tolerated. CONCLUSION: These results demonstrated the safety and tolerability of gilteritinib incorporated into an induction and consolidation chemotherapy regimen, and as single-agent maintenance therapy for patients with newly diagnosed FLT3-mutant AML. The data herein provide an important framework for the design of randomized trials comparing gilteritinib with other FLT3 inhibitors.
- 19 June 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (8) , 1254-1264
Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination therapy has improved outcomes in unfit patients but no prospective study has assessed ven/HMA versus 7&3 as initial therapy in older, fit patients. Given no studies and expectation of ven/HMA use in patients outside of trial criteria, we evaluated retrospective outcomes among newly diagnosed patients. A nationwide electronic health record (EHR)‐derived database and the University of Pennsylvania EHR identified 312 patients receiving 7&3 and 488 receiving ven/HMA who were 60–75 years old without history of organ failure. Ven/HMA patients were older and more likely to have secondary AML, adverse cytogenetics, and adverse mutations. Median overall survival (OS) for patients receiving intensive chemotherapy was 22 versus 10 months for ven/HMA (HR 0.53, 95% CI 0.40–0.60). Controlling for measured baseline characteristic imbalances reduced survival advantage by half (HR 0.71, 95% CI 0.53–0.94). A sub‐group of patients with equipoise, likelihood at least 30%–70% of receiving either treatment, had similar OS outcomes (HR 1.10, 95% CI 0.75–1.6). Regarding safety outcomes, 60‐day mortality was higher for ven/HMA (15% vs. 6% at 60 days) despite higher documented infections and febrile neutropenia for 7&3. In this multicenter real‐word dataset, patients selected for intensive chemotherapy had superior OS but a large group had similar outcomes with ven/HMA. Prospective randomized studies, controlling for both measured and unmeasured confounders, must confirm this outcome.
- 19 June 2023
- Published by Wiley in American Journal of Hematology
- Vol. 98 (8) , 1254-1264
Real‐world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Intensive chemotherapy with cytarabine and anthracycline (7&3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination therapy has improved outcomes in unfit patients but no prospective study has assessed ven/HMA versus 7&3 as initial therapy in older, fit patients. Given no studies and expectation of ven/HMA use in patients outside of trial criteria, we evaluated retrospective outcomes among newly diagnosed patients. A nationwide electronic health record (EHR)‐derived database and the University of Pennsylvania EHR identified 312 patients receiving 7&3 and 488 receiving ven/HMA who were 60–75 years old without history of organ failure. Ven/HMA patients were older and more likely to have secondary AML, adverse cytogenetics, and adverse mutations. Median overall survival (OS) for patients receiving intensive chemotherapy was 22 versus 10 months for ven/HMA (HR 0.53, 95% CI 0.40–0.60). Controlling for measured baseline characteristic imbalances reduced survival advantage by half (HR 0.71, 95% CI 0.53–0.94). A sub‐group of patients with equipoise, likelihood at least 30%–70% of receiving either treatment, had similar OS outcomes (HR 1.10, 95% CI 0.75–1.6). Regarding safety outcomes, 60‐day mortality was higher for ven/HMA (15% vs. 6% at 60 days) despite higher documented infections and febrile neutropenia for 7&3. In this multicenter real‐word dataset, patients selected for intensive chemotherapy had superior OS but a large group had similar outcomes with ven/HMA. Prospective randomized studies, controlling for both measured and unmeasured confounders, must confirm this outcome.